Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections

Sotrovimab, an antibody active against severe acute respiratory syndrome coronavirus 2 that neutralizes antibodies, reduced the risk of COVID-19-related hospitalization or death in studies conducted before the emergence of the Omicron variant. The objective of this study is to evaluate the clinical...

Full description

Bibliographic Details
Published in:	Viruses
Main Authors:	Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Yoshihisa Ishiura, Tomoki Ito
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Subjects:	sotrovimab monoclonal antibody COVID-19 Omicron variant SARS-CoV-2
Online Access:	https://www.mdpi.com/1999-4915/15/6/1300

Similar Items

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
by: Jessica J. Tuan, et al.
Published: (2023-04-01)

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
by: Carson K. L. Lo, et al.
Published: (2024-01-01)

Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2
by: Alwaleed Behzad, et al.
Published: (2024-02-01)

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England
by: Vishal Patel, et al.
Published: (2024-04-01)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
by: Gaetano Cicchitto, et al.
Published: (2022-12-01)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
by: Daniele Focosi, et al.
Published: (2022-08-01)

Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma
by: Naoyuki Miyashita, et al.
Published: (2025-05-01)

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
by: Kana Fujimoto, et al.
Published: (2022-12-01)

Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data
by: Antonio Russo, et al.
Published: (2024-01-01)

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
by: Fulvia Mazzaferri, et al.
Published: (2022-11-01)

Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
by: Supavit Chesdachai, et al.
Published: (2024-03-01)

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
by: Mindy M. Cheng, et al.
Published: (2023-01-01)

Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
by: Line Lundegaard Bang, et al.
Published: (2024-09-01)

Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation
by: Gianpaolo Marcacci, et al.
Published: (2022-08-01)

Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study
by: Antonio Russo, et al.
Published: (2025-02-01)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
by: Ahmed Zaqout, et al.
Published: (2022-11-01)

Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study
by: Myriam Drysdale, et al.
Published: (2024-07-01)

CLINICAL EVALUATION OF OMICRON SUBVARIANT BA. 2- A HOSPITAL BASED STUDY
by: Pratiti Datta, et al.
Published: (2023-06-01)

Sotrovimab: una opción terapéutica en trasplante pulmonar
by: Rosa Gutiérrez-Larraya-Sánchez-Andrade, et al.
Published: (2024-01-01)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
by: Federico Baldi, et al.
Published: (2023-01-01)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
by: Luca Cegolon, et al.
Published: (2023-05-01)

Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
by: Sean W. X. Ong, et al.
Published: (2022-03-01)

Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19
by: Sacha Satram, et al.
Published: (2023-09-01)

Research of Epidemiologic Feature and Control of SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
by: Yu WU, Jue LIU, Min LIU, Wannian LIANG
Published: (2022-10-01)

The epidemiology and phylogenetic trends of Omicron subvariants from BA.5 to XBB.1 in Taiwan
by: Jih-Jin Tsai, et al.
Published: (2024-11-01)

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
by: Alina Seidel, et al.
Published: (2023-04-01)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
by: Hao Zhou, et al.
Published: (2022-06-01)

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase
by: Neil R. Aggarwal, et al.
Published: (2023-03-01)

Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2
by: Costanza Di Chiara, et al.
Published: (2022-03-01)

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
by: Cécile Hérate, et al.
Published: (2023-06-01)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
by: Wanting Li, et al.
Published: (2023-08-01)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023-01-01)

Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
by: Ivan Gentile, et al.
Published: (2023-12-01)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
by: David Totschnig, et al.
Published: (2022-01-01)

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
by: Daniele Focosi, et al.
Published: (2024-01-01)

Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe
by: Evangelia Georgia Kostaki, et al.
Published: (2022-12-01)

What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
by: Andrea De Vito, et al.
Published: (2023-08-01)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
by: Carolina Torres, et al.
Published: (2023-01-01)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
by: Minrun Duan, et al.
Published: (2023-12-01)

Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023
by: Jianpeng Cai, et al.
Published: (2024-12-01)